Liver Illness and Psoriatic Patients.

Abstract

Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world's population. Systemic treatments, including methotrexate and cyclosporin, are associated with potential hepatotoxicity, due to either direct liver damage or immunosuppression or both immunomediated and a direct liver injury; therefore, treatment of patients with psoriasis poses a therapeutic challenge. The aim of this minireview is to help clinicians in the management of psoriatic patients who develop signs of liver dysfunction. To find relevant articles, a comprehensive search was performed on PubMed, EMBASE, and Cochrane with appropriate combinations of the following keywords being considered: viral hepatitis, nonalcoholic fatty liver disease, psoriasis, hepatotoxicity, drug toxicity, cholestasis, and autoimmune liver diseases.

• Authors: Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani
• Journal: BioMed research international (Biomed Res Int) Vol. 2018 Pg. 3140983 ( 2018) ISSN: 2314-6141 [Electronic] United States
• PMID: 29546055 (Publication Type: Journal Article, Review)

Chemical References

• Cyclosporine
• Methotrexate

Topics

• Autoimmune Diseases (chemically induced, epidemiology, pathology)
• Chemical and Drug Induced Liver Injury (epidemiology, pathology)
• Cyclosporine (adverse effects, therapeutic use)
• Humans
• Inflammation (chemically induced, epidemiology)
• Liver (drug effects, pathology)
• Liver Diseases (epidemiology, pathology)
• Methotrexate (adverse effects, therapeutic use)
• Psoriasis (complications, drug therapy, epidemiology, pathology)